Celldex Therapeutics, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Celldex completed a $323.8M underwritten public offering in April 2026, bringing cash to $717.6M as of June 30, 2026 (vs. $451.5M on March 31, 2026). The company enrolled 1,939 patients across two Phase 3 chronic spontaneous urticaria trials (EMBARQ-CSU 1 and 2), completing enrollment six months ahead of schedule across 43 countries and 500+ sites; topline data expected September/October 2026 with BLA filing planned for 2027. Phase 1 data for bispecific CDX-622 showed rapid, dose-dependent tryptase reductions with good tolerability; Phase 2 atopic dermatitis data expected late 2026. Company discontinuing prurigo nodularis program after Phase 2 failed primary endpoints.
Why this rating
Capital raise represents 25% of market cap, extending runway to 2028. Phase 3 enrollment ahead of schedule is operationally positive; failure in PN offsets. Near-term data catalyst material but uncertain.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.